Skip to main content
. 2023 Jan 11;12:1064722. doi: 10.3389/fonc.2022.1064722

Table 2.

PAX1m levels stratified by low-, medium-, and high-risks of CIN2+, CIN3+ and ESCC.

Variable OR/Adjusted OR (95%CI) a P for trend b
PAX1 m Low
N = 93
Moderate
N = 51
High
N = 74
 Median (range) 20.4 (16.3-22.3) 10.6 (9.11-14.35) 6.4 (1.1-9.0)
 OR, CIN2+ 1.0 1.43 (0.62-3.28) 12.52 (2.85-55.00) <0.001
P 0.404 0.001
 OR, CIN3+ 1.0 2.21 (1.10-4.44) 20.61 (8.08-52.57) <0.001
P 0.025 <0.001
 OR, ESCC 1.0 3.76 (0.33-42.46) 34.07 (4.45-261.08) <0.001
P 0.285 0.001
PAX1m Model 1 c
 OR, CIN2+ 1.0 1.36 (0.58-3.18) 11.98 (2.68-53.65) <0.001
P 0.473 0.001
 OR, CIN3+ 1.0 2.00 (0.98-4.08) 19.27 (7.39-50.22) <0.001
P 0.056 <0.001
 OR, ESCC 1.0 3.20 (0.27-37.08) 24.85 (3.17-194.67) <0.001
P 0.353 0.002

a ORs and 95%CI were calculated with the use of the logistic regression.

b P for trend, from a 1 degree-of-freedom trend test.

c The following variables were included to control for the effects of PAX1m: hrHPV [other hrHPV (+) except HPV16/18, HPV16/18 (+)] and cytology (<LSIL, LSIL+).